ITM Builds New Production Site in Munich Area
ITM Isotopen Technologien Mnchen AG (ITM), a radiopharmaceutical group of companies, announced today the lease of a new building in Neufahrn near Munich to increase the production capacity of no-carrier-added (n.c.a.)
- ITM Isotopen Technologien Mnchen AG (ITM), a radiopharmaceutical group of companies, announced today the lease of a new building in Neufahrn near Munich to increase the production capacity of no-carrier-added (n.c.a.)
- Lutetium-177, known under the brand name EndolucinBeta, is an innovative medical isotope that has been used successfully in cancer therapy.
- The long term lease of the approximately 5000 m2 building in the NOVA industrial estate offers ideal conditions for ITM.
- "We are very pleased with the opportunities that the new location offers," says Steffen Schuster, CEO of ITM.